9H4 logo

LungLife AI DB:9H4 Stock Report

Last Price

€0.10

Market Cap

€3.3m

7D

-6.1%

1Y

-86.4%

Updated

25 Dec, 2024

Data

Company Financials +

9H4 Stock Overview

A diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. More details

9H4 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

LungLife AI, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for LungLife AI
Historical stock prices
Current Share PriceUK£0.10
52 Week HighUK£0.75
52 Week LowUK£0.087
Beta-0.17
1 Month Change1.02%
3 Month Change-22.27%
1 Year Change-86.37%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.64%

Recent News & Updates

Recent updates

Shareholder Returns

9H4DE BiotechsDE Market
7D-6.1%-0.8%-1.6%
1Y-86.4%-13.0%6.8%

Return vs Industry: 9H4 underperformed the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 9H4 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 9H4's price volatile compared to industry and market?
9H4 volatility
9H4 Average Weekly Movement14.4%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 9H4's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 9H4's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20098Paul Paganolunglifeai.com

LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019.

LungLife AI, Inc. Fundamentals Summary

How do LungLife AI's earnings and revenue compare to its market cap?
9H4 fundamental statistics
Market cap€3.33m
Earnings (TTM)-€4.30m
Revenue (TTM)€27.90k

119.3x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9H4 income statement (TTM)
RevenueUS$29.00k
Cost of RevenueUS$0
Gross ProfitUS$29.00k
Other ExpensesUS$4.50m
Earnings-US$4.47m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin100.00%
Net Profit Margin-15,403.45%
Debt/Equity Ratio0%

How did 9H4 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 07:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LungLife AI, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adam BarkerGoodbody Stockbrokers
Andrew WhitneyInvestec Bank plc (UK)
Jens LindqvistInvestec Bank plc (UK)